Adverse effects of linezolid in the treatment of drug-resistant tuberculosis combined with diabetic peripheral neuropathy.

OBJECTIVE

This aimed to observe the adverse effects of linezolid on nerve conduction velocity in patients with drug-resistant tuberculosis combined with diabetic peripheral neuropathy.

METHODS

Patients hospitalized in our hospital from March 2018 to March 2022 were divided into the drug-resistant tuberculosis (DRTB) group, type 2 diabetes peripheral neuropathy (DPN) group, and type 2 diabetic peripheral neuropathy combined with drug-resistant tuberculosis (DM-DRTB) group. The drug-resistant TB treatment regimen used linezolid with antituberculous drugs. Neurophysiological examinations were performed on the patients before and 2 months after treatment, the conduction velocities of the superficial peroneal nerve and peroneal nerve of the lower limbs of the three groups were recorded, and the conduction velocities of the deep peroneal nerve, superficial peroneal nerve, common peroneal nerve, tibial nerve, and femoral nerve of the lower limb motor nerves of the three groups were compared and statistically analyzed.

RESULTS

After 2 months of linezolid treatment, the sensory nerve conduction velocities of the superficial peroneal nerve and sural nerve of the lower limb in the DRTB group and the DM-DRTB group significantly decreased, and the difference was statistically significant (p < 0.05). There was no significant decrease in the motor nerve conduction velocities of the deep peroneal nerve, superficial peroneal nerve, common peroneal nerve, tibial nerve, or femoral nerve of the lower limb in the DRTB and the DM-DRTB groups, and the differences were not statistically significant (p > 0.05).

CONCLUSION

Linezolid can slow lower limb sensory nerve conduction velocity in patients with DRTB and DM-DRTB; however, the effect on lower limb motor nerves was not significant.